Adial Pharmaceuticals
ADIL
13 hedge funds and large institutions have $2.75M invested in Adial Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, reducing their positions, and 0 closing their positions.
96% more capital invested
Capital invested by funds: $1.41M → $2.75M (+$1.35M)
86% more funds holding
Funds holding: 7 → 13 (+6)
0.01% more ownership
Funds ownership: 0.01% → 0.01% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.26M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$307K |
| 3 |
Millennium Management
New York
|
+$280K |
| 4 |
RWM
Raffa Wealth Management
Washington,
District of Columbia
|
+$200K |
| 5 |
Jane Street
New York
|
+$146K |
Top Sellers
ADIL Hedge Fund Activity: Q1 2019 in Review
13 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q1 2019, worth a combined $2.75M — up 96% from $1.41M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ADIL positions and 0 closed out — a net gain of 6 holders — while 5 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.26M.
- 13 institutional investors held Adial Pharmaceuticals (ADIL) as of Q1 2019, up from 7 in Q4 2018.
- Funds reported $2.75M of Adial Pharmaceuticals stock for Q1 2019, up 96% quarter-over-quarter.
- 6 funds opened new Adial Pharmaceuticals positions in Q1 2019 and 0 closed out, a net change of +6 holders.
- The largest Adial Pharmaceuticals buyer in Q1 2019 was Vanguard Group, an estimated $1.26M added.
Based on aggregated 13F filings for Q1 2019.